Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
226 results about "Vesicle/vacuole" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Membrane-enclosed spherules that serve as subcellular packaging for nutrients, waste, or secretory compounds, or as vehicles to and from the cell membrane; do not use for artificial lipid vesicles (see MEMBRANE MODEL).
Lipid vesicle compositions and methods of use
ActiveUS20120177724A1Increase load capacityImprove the level ofPeptide/protein ingredientsMicroencapsulation basedAntigenVesicle/vacuole
The invention provides delivery systems comprised of stabilized multilamellar vesicles, as well as compositions, methods of synthesis, and methods of use thereof. The stabilized multilamellar vesicles comprise terminal-cysteine-bearing antigens or cysteine-modified antigens, at their surface and / or internally.
Owner:MASSACHUSETTS INST OF TECH +1
High-efficiency fusogenic vesicles, methods of producing them, and pharmaceutical compositions containing them
Owner:PEVION BIOTECH
Lipid vesicle compositions and methods of use
ActiveUS20110229529A1Increase load capacityLong release profileOrganic active ingredientsVirusesDiagnostic agentVesicle/vacuole
Owner:MASSACHUSETTS INST OF TECH
Biological component comprising artificial membrane
InactiveUS7713544B2Improved performance characteristicsMinimize adhesionMaterial nanotechnologyMicroorganismsAmount of substanceMembrane mimetic
A biocompatible biological component is provided comprising a membrane-mimetic surface film covering a substrate. Suitable substrates include hydrated substrates, e.g. hydrogels which may contain drugs for delivery to a patient through the membrane-mimetic film, or may be made up of cells, such as islet cells, for transplantation. The surface may present exposed bioactive molecules or moieties for binding to target molecules in vivo, for modulating host response when implanted into a patient (e.g. the surface may be antithrombogenic or antiinflammatory) and the surface may have pores of selected sizes to facilitate transport of substances therethrough. An optional hydrophilic cushion or spacer between the substrate and the membrane-mimetic surface allows transmembrane proteins to extend from the surface through the hydrophilic cushion, mimicking the structure of naturally-occurring cells. An alkylated layer directly beneath the membrane-mimetic surface facilates bonding of the surface to the remainder of the biological component. Alkyl chains may extend entirely through the hydrophilic cushion when present. To facilitate binding, the substrate may optionally be treated with a polyelectrolyte or alternating layers of oppositely-charged polyelectrolytes to facilitate charged binding of the membrane-mimetic film or alkylated layer beneath the membrane-mimetic film to the substrate. The membrane-mimetic film is preferably made by in situ polymerization of phospholipid vesicles.
Owner:EMORY UNIVERSITY
Biodegradable polymer vesicles and preparation and application thereof
InactiveCN101792516AEfficient packagingEliminate drug resistancePharmaceutical non-active ingredientsPolymer sciencePolyethylene glycol
The invention relates to a medicament carrier and a preparation method thereof, in particular to a medicament delivery system comprising biodegradable polymer vesicles with asymmetric membranes. The invention discloses the biodegradable polymer vesicles and preparation and application thereof. The biodegradable polymer vesicles are prepared from A-B-C type block polymer, wherein a block A is polyethylene glycol (PEG) distributed on outer surfaces of the vesicles; a block B is hydrophobic biodegradable polymer to form the nucleuses of the vesicles; and a block C is polyelectrolyte distributed on inner walls of the vesicular membranes and used for efficiently loading medicaments with opposite electric charge. The biodegradable polymer vesicles are formed in aqueous solution directly, can efficiently load protein and polypeptide medicaments, nucleic acid medicaments and micro-molecular medicaments, and are expected to be applied to the protein therapy and the combination therapy of cancers.
Owner:SUZHOU UNIV
Synthetic Lipid Rafts and Methods of Use
Compositions and methods for delivering cargo to cells are provided. One aspect provides a synthetic vesicle containing caveolin 1 or a fragment thereof in an amount effective to form lipid rafts in the vesicle. The synthetic vesicles can be used to deliver polynucleotides, proteins, therapeutic agents, or a combination thereof to specific membrane-bound compartments of a cell. In certain aspects, the synthetic vesicles can deliver cargo to cellular organelles such as mitochondria.
Owner:GENCIA
Plasma membrane vesicles comprising functional transmembrane proteins
InactiveUS20170112773A1Enhances and restores cellular gap junction communicationEnhances and restores endogenous CFTR functionOrganic active ingredientsPharmaceutical non-active ingredientsMedicineVesicle/vacuole
Provided herein are methods and compositions for treating a subject in need thereof comprising administering an effective amount of vesicles with functional transmembrane proteins embedded in the plasma membrane. Also provided herein are methods of restoring gap junctional communication comprising the administration of an effective amount of vesicles.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Anti-aging co-transport nanolipid vesicle and preparation method and application thereof
InactiveCN109044921AIncrease loadStable vesicle structureCosmetic preparationsToilet preparationsCholesterolWater insoluble
The invention provides an anti-aging co-transport nano lipid vesicle and a preparation method and application thereof, and belongs to the technical field of functional cosmetics. The anti-aging co-transport nano lipid vesicle comprises the following components in parts by weight: 0.02-32 parts of an anti-aging active component, 11.1-65 parts of a nano lipid vesicle, and 3-88 parts of water, wherein the nano lipid vesicle comprises the following raw materials in parts by weight: 5.0-20.0 parts of a nonionic surfactant, 5.0-30.0 parts of water-soluble alcohol, 1.0-10.0 parts of compound phosphatide, and 0.1-5.0 parts of cholesterol; and the anti-aging active component includes a water insoluble anti-aging component and / or a water soluble anti-aging component. According to the preparation method, the anti-aging active components are loaded in the same nano lipid vesicle, so that transdermal co-transport of multi-target-point anti-aging active components of various anti-aging mechanisms can be realized; and synergistic interaction is realized, and thus the anti-aging effect is improved.
Owner:WUHAN BEST CARRIER NANO TECH
Liposomal particles, methods of making same and uses thereof
ActiveUS20160310425A1Not stableSpecial deliveryGenetic material ingredientsInstabilityImmunogenicity
Liposomes termed as small unilamellar vesicles (SUVs), can be synthesized in the 20-50 nm size range, but encounter challenges such as instability and aggregation leading to inter-particle fusion. This limits their use as a therapeutic delivery agent. Increasing the surface negative charge of SUVs, via the attachment of anionic entities such as DNA / RNA, increases the colloidal stability of these vesicles. Additionally, the dense spherical arrangement and radial orientation of nucleic acids exhibits unique chemical and biological properties, unlike their linear counterparts. These liposomal particles, are non-toxic and though anionic, can efficiently enter cells without the aid of ancillary cationic transfection agents in a non-immunogenic fashion. These exceptional properties allow their use as delivery agents for gene regulation in different therapies and offer an alternative platform to metal core spherical nucleic acids.
Owner:NORTHWESTERN UNIV +1
Indocyanine green composite nanoparticle as well as preparation method and application thereof
ActiveCN104922671AImprove tumor treatment effectImprove targetingPowder deliveryEnergy modified materialsTumor targetHydrophobic polymer
The invention provides an indocyanine green composite nanoparticle which comprises indocyanine green, a hydrophobic polymer, polyethylene glycol derived phospholipid and a cancer cell membrane. The indocyanine green is encircled by the hydrophobic polymer and forms a sphere-like structure together with the hydrophobic polymer; the polyethylene glycol derived phospholipid penetrates the cancer cell membrane and forms a vesicle structure together with the cancer cell membrane; the sphere-like structure is wrapped in the vesicle structure. The invention further provides a preparation method and application of the indocyanine green composite nanoparticle. When the indocyanine green composite nanoparticle is applied, the indocyanine green composite nanoparticle has an efficient tumor targeting property, the indocyanine green can hardly gather and high stability is realized.
Owner:珠海中科先进技术研究院有限公司
Preparation method of core-shell structured Fe3O4@MCM-41 magnetic nano material
InactiveCN103551094AThermodynamically stableMicroballoon preparationMicrocapsule preparationEthylenediamineSODIUM DODECYL BENZENE SULFONATE
The invention provides a preparation method of a core-shell structured Fe3O4@MCM-41 magnetic nano material, and relates to a method for synthesizing Fe3O4 magnetic nano material from a vesicle phase. The preparation method of the core-shell structured Fe3O4@MCM-41 magnetic nano material aims to solve the problems of uneven core-shell structure and small specific surface area of the magnetic nano material. The preparation method comprises the following steps of: 1, preparing a vesicle phase solution from hexadecyl trimethyl ammonium bromide and sodium dodecyl benzene sulfonate; 2, dissolving FeCl3 and FeSO4 in secondary distilled water, and then adding the vesicle phase solution to the obtained iron salt solution, adding quadrol to adjust the pH value of the system after ultrasonic treatment to obtain a black suspension; and 3, adding hexadecyl trimethyl ammonium bromide and TEOS (Tetra Ethyl Ortho Silicate) to the black suspension, carrying out a crystallization reaction after pH adjustment, washing and drying the solid-phase crystals and then roasting the solid-phase crystals to obtain the magnetic nano material. The preparation method of the core-shell structured Fe3O4@MCM-41 magnetic nano material is characterized in that the vesicles formed by compounding an anionic surfactant with a cationic surfactant are taken as micro-reactors, the thermodynamic performance of the system is stable, and in the meantime, the specific surface area of the magnetic nano material is large.
Owner:QIQIHAR UNIVERSITY
High-polymer vesicle containing AIE (aggregation-induced emission) molecules as well as preparation method and application of high-polymer vesicle
InactiveCN105524441AOvercoming the disadvantages of aggregation-induced fluorescence quenchingAvoid identificationOrganic active ingredientsPowder deliveryCopolymerClinical imaging
The invention belongs to the field of high-polymer materials and discloses a high-polymer vesicle containing AIE (aggregation-induced emission) molecules as well as a preparation method and an application of the high-polymer vesicle. The high-polymer vesicle is mainly formed through self-assembly of the AIE molecules and amphiphilic block copolymers; the outer layer and the inner layer of a high-polymer vesicle film are hydrophillic layers, each hydrophillic layer is formed by hydrophilic chain sections in the amphiphilic block copolymers, and a film intermediate layer between the outer layer and the inner layer is formed by hydrophobic chain sections in the amphiphilic block copolymers and the AIE molecules. The high-polymer vesicle has high fluorescence intensity and can meet different fluorescent staining demands. The preparation method is simple and feasible, the production efficiency is high, and the repeatability is good. The high-polymer vesicle can be used for related fields of optical bioimaging, biological detection and clinical imaging, high-polymer vesicle research and the like.
Owner:SOUTH CHINA UNIV OF TECH
Vesicular system and uses thereof
ActiveUS20120129270A1Overcome difficultiesModulate its functionPharmaceutical non-active ingredientsMaterial analysisHeteroatomBackbone chain
Disclosed is a vesicular system comprising a surface with a vesicle immobilized thereon. The immobilized vesicle has a circumferential membrane of an amphiphilic polymer. The vesicle is coupled to a surface by means of a molecule with a non-polar moiety. The non-polar moiety comprises a main chain of 3 to about 30 carbon atoms and 0 to about 12 heteroatoms selected from Si, O, S, and Se. The molecule with the non-polar moiety is coupled to the surface via a covalent or non-covalent bond. A portion of the non-polar moiety is integrated in the circumferential membrane.
Owner:AGENCY FOR SCI TECH & RES
Brain specific exosome based diagnostics and extracorporeal therapies
InactiveUS20170014450A1Reliable and inexpensive and portable and rapid and simple approachMinimally invasive, inexpensive, portable, and reliableCell receptors/surface-antigens/surface-determinantsImmunoglobulins against animals/humansPsa ncamPhosphorylation
Disclosed are methods, compositions, devices, and kits for the isolation of brain-specific exosomes. Specifically, methods, compositions, devices, and Unbound kits comprising an isolated brain-specific extracellular vesicle or exosome joined to a first binding agent that is specific for tau, β-amyloid, SlOO β, neuron-specific enolase, glycoprotein A2B5, CD133, NQ01, synaptophysin, neuronal nuclei, MAB 1569, polysialic acid-neural cell adhesion molecule (PSA-NCAM), or neurogenic differentiation 1 (NeuroD or Beta2), or glycosylated or phosphorylated forms of these molecules, are provided.
Owner:EXOSOME SCI
New application of ginkgolide B
InactiveCN102018702APromote apoptosisPromote growthOrganic active ingredientsUrinary disorderCanine kidneyCytotoxicity
The invention discloses application of ginkgolide B to preparation of medicament for preventing and / or treating autosomal dominant polycystic kidney disease. A madin-darby canine kidney (MDCK) vesicle model is used for screening to find that the ginkgolide B inhibits formation and growth of vesicles. An experimental result shows that: the ginkgolide B has an obvious inhibiting effect on the formation and growth of MDCK vesicles and the effect of the ginkgolide B is in dose response relationship; the ginkgolide B has no cytotoxicity to MDCK cells, so that the vesicle inhibiting effect of the ginkgolide B is independent of the cytotoxicity; the ginkgolide B does not obviously induce MDCK cell apoptosis, so that the vesicle inhibiting effect of the ginkgolide B is independent of cell apoptosis promotion of the ginkgolide B; the ginkgolide B can promote the MDCK cells or vesicles to form tubular structures; and the effect is in dose response relationship; and the ginkgolide B has an inhibiting effect on the growth of the embryonic kidney vesicles. The ginkgolide B provides experimental data for development of a specific medicament for preventing and / or treating autosomal dominant polycystic kidney disease.
Owner:PEKING UNIV
Polymer vesica with antibacterial nano silver deposited on surface and preparation method thereof
InactiveCN102432974AWith temperatureHas dual pH sensitivityPharmaceutical non-active ingredientsCurative effectBiocompatibility Testing
The invention belongs to the field of nano biological medical materials and particularly relates to polymer vesica with the surface deposited with antibacterial nano silver and a preparation method thereof. Amphipathic block polymers are self-assembled by a cosolvent method to form the vesica, and then the nano silver is generated in situ on the surface of the vesica. The polymer vesica has biocompatibility and has certain temperature and pH sensitivity; a cavity structure of the vesica can wrap various medicines; and simultaneously, due to the existence of the nano silver, the vesica also has the curative effects of sterilization and bactriostasis.
Owner:TONGJI UNIV
Lecithin carrier vesicles and methods of making the same
InactiveUS20110318406A1Small sizeHigh shear mixingBiocideDough treatmentVesicle/vacuoleBULK ACTIVE INGREDIENT
A hydrated lecithin carrier vesicle composition includes a lecithin-derived membrane-forming lipid vesicle in conditioned water for incorporation of an active ingredient to form a dispersed composition. A method of making the hydrated lecithin carrier vesicle includes using lecithin having not more than about 80% w / w phosphatidylcholine in the presence of conditioned water.
Owner:BIO UP MIMETIC TECH INC
Aquaporin based thin film composite membranes
Present invention relates to a thin film composite membrane wherein a thin selective layer, having incorporated amphiphilic vesicles, is supported by a microporous substrate. A process of preparing the thin film composite membrane and its use are also disclosed.
Owner:NANYANG TECH UNIV
PH and temperature sensitive nano-vesicles and preparing method and application thereof
ActiveCN105997879AProlong blood circulation timeImprove permeabilityOrganic active ingredientsEchographic/ultrasound-imaging preparationsEthylenediaminePolymer science
The invention belongs to the fields of high polymer chemistry and biomedical engineering, and particularly discloses a pH and temperature sensitive polymer. The polymer is composed of a hydrophilic polyethylene glycol segment, and a lyophobic poly-(aspartic acid-diethyl-ethylenediamine-co-histamine-co-diisopropyl ethylenediamine) segment, and the ratio of the hydrophilic segment to the lyophobic segment is (1:10)-(1:12). The pH and temperature sensitive polymer can be used for preparing nano-vesicles loaded with hydrophilic anti-tumor drugs or / and ultrasonic contrast agents, and the nano-vesicles can be used for preparing tumor diagnosis drugs or tumor treatment drugs.
Owner:SUN YAT SEN UNIV
Subunit vaccine delivery platform for robust humoral and cellular immune responses
ActiveUS9808517B2Suppress immunityModulates T-Cell Cycling and ExpansionSsRNA viruses negative-senseBacterial antigen ingredientsVaccine deliveryVesicle/vacuole
Owner:CORNELL UNIVERSITY
Macrophage drug-loaded MP (microparticle) preparation and preparation method thereof
ActiveCN109893515APromote enrichmentEfficient killingPharmaceutical non-active ingredientsAntineoplastic agentsSide effectCell vesicle
The invention discloses a macrophage drug-loaded MP (microparticle) preparation and a preparation method thereof. The macrophage drug-loaded MP preparation comprises cell vesicles and drug small molecule effective components wrapped in the cell vesicles, wherein the cell vesicles are released by apoptosis of mannose modified macrophages. The drug-loaded microparticles can be highly enriched in tumor tissue and more easily absorbed by M2 type tumor-related macrophages, the antipolarization effect of small molecule drugs on M2 type tumor-related macrophages is improved, the tumor microenvironment is improved, killing of tumor cells is enhanced, the problems that small molecule drugs cannot be effectively enriched or target and antipolarize M2 type tumor-related macrophages at tumor sites canbe solved, and toxic and side effects of the small molecule drugs on organisms are also reduced.
Owner:HUAZHONG UNIV OF SCI & TECH
Surfactant Mixtures for Improving the Deposition of Active Substances and for Reducing the Skin Irritant Action
InactiveUS20120183591A1Improve efficiencyMore cost-effectivelyCosmetic preparationsBiocideAlcoholPolyol
A cosmetic or pharmaceutical rinse-off formulation contains 0.2% by weight to 20% by weight of a phase A; 0.1% by weight to 50% by weight of an active substance; a detergent; and the remainder being water. The phase A is a mixture of 20% by weight to 90% by weight of a surfactant mixture of isethionates, acyl lactylates and one of alkyl glutamates and alkyl glucosides and 10% by weight to 80% by weight of water, alcohol, polyol or mixtures thereof. The phase A forms multilamellar vesicles. The cosmetic or pharmaceutical rinse-off formulation is a clear product with the multilamellar vesicles of phase A having an average diameter of less than 100 nm.
Owner:IFAC INST FUR ANGEWANDTE COLLOIDTECH
Substance-encapsulating vesicle and process for producing the same
ActiveUS20130202711A1High usefulnessEasily and efficiently producedGranular deliveryLiposomal deliveryVesicle/vacuoleAqueous medium
Provided is a method for easily and efficiently producing encapsulated substance vesicles wherein a substance is encapsulated in the cavity of vesicles obtained by polymer self-assembly. Empty vesicles that have membranes comprising a first polymer that is a block copolymer with uncharged hydrophilic segments and a first kind of charged segments and a second polymer with a second kind of charged segments that carry a charge that is the opposite of said first kind of charged segments as well as spaces that are enclosed by said membranes are mixed in an aqueous medium with the substance that is to be encapsulated in the spaces.
Owner:JAPAN SCI & TECH CORP
Method for preparing multi-layer bio-based vesica capable of releasing insulin
ActiveCN105078890AAchieve controlled releaseImprove stabilityPeptide/protein ingredientsMetabolism disorderMicrosphereBiocompatibility Testing
Owner:JIANGNAN UNIV
Methods for extracellular vesicle isolation and selective removal
Disclosed is a method for the isolation of extracellular vesicles, including exosomes, from a liquid sample, the method comprising the steps of: adjusting the pH of a liquid sample comprising extracellular vesicles to a preselected, binding pH; contacting the liquid sample with silicon carbide, wherein at the preselected, binding pH, the extracellular vesicles bind to the silicon carbide; and eluting the bound extracellular vesicles from the silicon carbide. The liquid samples can comprise bodily fluids. Further disclosed is a method for producing a liquid sample, substantially depleted of extracellular vesicles, including exosomes.
Owner:NORGEN BIOTEK CORP
Implantable drug delivery device and methods for treatment of the bladder and other body vesicles or lumens
ActiveUS9586035B2Minimize irritationEasy loadingOrganic active ingredientsPharmaceutical delivery mechanismControlled drugsDrug reservoir
Owner:MASSACHUSETTS INST OF TECH
Polymer vesicle of double-loading anthracycline ring medicine and photosensitizer, having bubble generation function, as well as preparation
ActiveCN108653733AGood curative effectMaintain stabilityOrganic active ingredientsPhotodynamic therapyBiocompatibility TestingTherapeutic effect
The invention relates to a polymer vesicle of a double-loading anthracycline ring medicine and a photosensitizer, having a bubble generation function, as well as preparation. A pH / temperature double-sensitive multifunctional polymer vesicle of hydrophilic inner cavity loaded anthracycline ring medicine and a hydrophobic film loaded photosensitizer, having the bubble generation function, is prepared by taking an amphiphilic triblock copolymer PCL-b-PEG-b-PCL as a material. The anthracycline ring medicine is wrapped with and loaded in the hydrophilic inner cavity by an ammonium hydrogen carbonate gradient active medicine loading method, ammonium hydrogen carbonate can be decomposed under the condition of low pH value or heating to generate carbon dioxide bubbles, the structure of the vesicleis broken and the wrapped medicines are released rapidly. After the medicines are delivered to the local part of tumor through EPR (enhanced permeability and retention) targeting, the therapeutic effect of the anthracene ring chemotherapeutic medicines on the tumor can be obviously improved under illumination. The polymer vesicle can serve as a medicine carrier to wrap and load hydrophilic and hydrophobic medicines simultaneously, has a stable structure, has high biocompatibility and degradability, and has a wide application prospect on the aspects of medicine delivery and controllable release and chemotherapeutic combined photothermal therapy on the tumor.
Owner:INST OF BIOMEDICAL ENG CHINESE ACAD OF MEDICAL SCI
Lipid vesicle compositions and methods of use
ActiveUS9149432B2Increase load capacityImprove the level ofPeptide/protein ingredientsMicroencapsulation basedAntigenVesicle/vacuole
The invention provides delivery systems comprised of stabilized multilamellar vesicles, as well as compositions, methods of synthesis, and methods of use thereof. The stabilized multilamellar vesicles comprise terminal-cysteine-bearing antigens or cysteine-modified antigens, at their surface and / or internally.
Owner:MASSACHUSETTS INST OF TECH +1
Polypeptide combination method for wrinkle reduction
InactiveCN108904317APromote generationElasticCosmetic preparationsToilet preparationsCell membraneCellular membrane fusion
The invention discloses a polypeptide combination method for wrinkle reduction. Through one or more polypeptides, the fusion of vesicles and a cell membrane is inhibited so that release of acetyl choline is inhibited. The polypeptide combination method utilizes a wrinkle reduction polypeptide composition with a mass concentration of 0.001% to 5%, a humectant with a mass concentration of 0.001%-10%, an antibacterial stabilizer with a mass concentration of 0.001%-2%, a preservative with a mass concentration of 0.001%-2% and a pH adjuster. The wrinkle reduction polypeptide composition comprises one or more of acetyl hexapeptide-8, palmitoyl pentapeptide-4, venom-like peptide and copper tripeptide-1 and the balance of deionized water and has a mass concentration of 0.001%-5%. According to thewrinkle production mechanism and different polypeptide action targets, the invention provides the wrinkle reduction polypeptide composition.
Owner:ZHEJIANG PEPTITES BIOTECH CO LTD
Intravenous oncolytic virus preparation and preparation method thereof
ActiveCN109288875AExtend cycle timeGood treatment effectViral/bacteriophage medical ingredientsPharmaceutical delivery mechanismSide effectOncolytic adenovirus
The invention relates to an intravenous oncolytic virus preparation and a preparation method thereof. The method performs transfection of a targeting polypeptide gene to a eukaryotic cell, and displays the targeting polypeptide on a cell membrane to obtain the gene engineering reconstructed cell strain capable of stably expressing the targeting polypeptide, The cell strain is used to extract nano-sized cell membrane vesicles with a uniform size, and then the oncolytic virus (OV) is loaded into the cell membrane vesicles with engineering reconstruction to synthesize an intravenous oncolytic virus complex which can be targeted for tumor delivery. The intravenous oncolytic virus preparation encapsulates the oncolytic virus in the cell membrane vesicles, and can effectively reduce the neutralizing effect of a neutralizing antibody on the oncolytic virus in the body, the cell membrane vesicle has targeting performance after gene engineering reconstruction, can achieve targeted delivery of the oncolytic virus and enrichment at the tumor site, and reduces the systemic side effects of the oncolytic virus.
Owner:厦门宏谱福生物科技有限公司
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com